Stephen Brunton
Stephen Brunton
Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed? [0.03%]
肥胖症背景下2型糖尿病的管理：如何预防或逆转体重增加？
Sharon W Lahiri
Sharon W Lahiri
A Case of Persistent Polyuria in an Insulin- Dependent Child With Diabetes [0.03%]
一例1型糖尿病患儿的尿崩症急诊病例分析
Swayamsidha Mangaraj,Arun Kumar Choudhury,Binoy Kumar Mohanty et al.
Swayamsidha Mangaraj et al.
Pharmacists' Impact on Glycemic Control Among Surgical Patients at a Large Academic Institution [0.03%]
大型学术机构药剂师对外科患者血糖控制的影响
Cynthia T Nguyen,Anna Seto,Robert Rushakoff et al.
Cynthia T Nguyen et al.
Timothy J Church,Stuart T Haines
Timothy J Church
In Brief Patients with severe insulin resistance require >2 units/kg of body weight or 200 units/day of insulin. Yet, many patients do not achieve glycemic targets despite using very high doses of insulin. Insulin can cause weight gain, whi...
Analysis of a Delivery Device Conversion for Insulin Aspart: Potential Clinical Impact in Veterans [0.03%]
关于天冬胰岛素输送装置转换的分析：退伍军人中的潜在临床影响
Caitlin M Moorman Spangler,Beth D Greck,Jancy H Killian
Caitlin M Moorman Spangler
In Brief Insulin therapies using a wide variety of delivery devices are available to accommodate individual patients' needs. In this study of veterans with diabetes, converting from insulin aspart delivered with vials and syringes to insuli...
Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes [0.03%]
insulin治疗新进展：长效胰岛素类似物甘精胰岛素300 U/ml 治疗糖尿病临床应用专家共识
John R White Jr
John R White Jr
In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. The EDITION clinical trial program showed that the use of Gla-30...
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies [0.03%]
利西那肽：一类新型的胰高血糖素样肽-1受体激动剂类肠降糖药物
Charles F Shaefer Jr
Charles F Shaefer Jr
In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or...
Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics [0.03%]
美国糖尿病协会、美国糖尿病教育者协会和饮食etics学院关于2型糖尿病自我管理教育与支持的联合立场声明
Margaret A Powers,Joan Bardsley,Marjorie Cypress et al.
Margaret A Powers et al.